JD Health Posts 32.37% Rise in Net Profit for First Half of Fiscal Year

Stock News
08/13

JD Health (06618) has released its interim results for the six months ended June 30, 2026, reporting a 15.9% increase in revenue to RMB 40.888 billion. Profit attributable to shareholders reached RMB 3.437 billion, marking a 32.37% increase from the same period last year, with basic earnings per share of RMB 1.08.

Non-International Financial Reporting Standards (non-IFRS) operating profit for the period came in at RMB 3.483 billion, up 40.3% year-on-year. The company attributed the strong performance to a favorable industry environment, including continued government support for the healthcare sector. In the first half of 2026, the State Council issued the "15th Five-Year Plan for Expanding Consumption," which explicitly supports health consumption and the development of new service formats such as health management, opening up long-term growth opportunities from the demand side.

Additionally, the National Health Commission's policy on promoting and regulating the application of "AI + Healthcare" has further encouraged the development of vertical industry large models and medical agents, providing policy support for technology-driven service innovation. The accelerated pace of industry standardization has also highlighted the value of full-chain supply chain layout and compliance operations, creating a favorable environment for JD Health to strengthen its competitive advantages and expand long-term growth.

During the reporting period, JD Health leveraged its core pharmaceutical supply chain capabilities to further solidify user trust and strengthen its leading market position. The company's non-IFRS operating profit margin improved from 7.0% to 8.5%. As a leading healthcare service provider, JD Health continues to implement its long-term business strategy centered on "experience, cost, and efficiency," driving sustained improvements in business growth and profitability. The company is actively promoting the integration of its self-operated supply chain capabilities with medical services, deepening partnerships across the industry chain, and steadily advancing the application of AI across diverse health consumption scenarios. Looking ahead, JD Health will focus on user needs, continuing to expand its online and offline health service boundaries to provide accessible, convenient, high-quality, and affordable health products and digital health solutions.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10